In a statement on Monday via its official X handle, the agency identified the product as Gold Vision Oxytocin Injection 10IU, which carries a fake registration number “A4-9566.” It explained that the injection was purportedly manufactured by Anhui Hongye Pharmaceutical Co., Ltd. in China and marketed by Gold Vision Medicals in Enugu.
NAFDAC said the discovery was made during a risk-based sampling survey, which also revealed other falsified products including A-tocin Injection, Extocin Injection, and Claxitodin Injection. All were reportedly linked to the same company and carried the same falsified registration number.
The agency stressed that the products are not listed in its database of registered medicines, confirming them as falsified.
Issuing a health risk alert, NAFDAC cautioned that such unregistered or counterfeit Oxytocin injections may contain wrong dosages, no active ingredients, or harmful contaminants. This could result in ineffective uterine contractions, postpartum haemorrhage, or even maternal death.
“Poor-quality oxytocin may also fail to control bleeding after childbirth, raising the risk of emergency interventions such as blood transfusions or surgery,” the statement read.
NAFDAC urged healthcare professionals and consumers to exercise vigilance and report suspected cases of substandard or falsified medicines to the nearest NAFDAC office.
This development comes amid rising concerns over unregistered drugs in circulation. The agency recently raised similar alarms over counterfeit batches of Postinor-2, an emergency contraceptive pill, warning that the fake versions posed serious health risks.
Leave a comment
Your email address will not be published. Required fields are marked *
